Cancer Research UK CTU gets £4.5mn for pancreatic cancer research

Modesto Morganelli
Febbraio 15, 2018

This includes work on the Primus trials, part of the Precision-Panc project which aims to develop personalised treatments for pancreatic cancer.

"This is particularly important for patients with hard to treat cancers, including pancreatic, oesophageal, lung and brain tumours, where options for treatment are limited and survival rates remain poor".

Scientists at the facility are now involved in research into new and better treatments for patients with brain tumours, pancreatic cancer, lung cancer and prostate cancer.

The Cancer Research UK, a charitable organization in the UK focusing on cancer research & healthcare, has offered funds worth £4.5 million for the Cancer Research UK Clinical Trials Unit (CTU) in Scotland after assessing a review report of all its clinical trial units.

Cancer Research UK's children's cancer expert Professor Pamela Kearns, who directs the CTU in Birmingham, said trials are vital in helping establish the effectiveness of adult treatments when applied to children.

"We believe that this approach will result in better treatment, by avoiding the side effects of the current "one size fits all" chemotherapy and offering treatments which will be more specific to the individual patient's tumour".

Nearly £4.5m is to be invested into cancer research in Scotland over the next five years. The overall survival rate in cancer patients has increased in the country over the last four decades and today, almost half of the patients survive the disease for almost 10 years.

In last 40 years, overall survival from cancer has doubled in the United Kingdom and today two in four people survive their cancer for at least 10 years. It ensures researchers can take full advantage of our most promising scientific discoveries and translate them into new tests and treatments for patients.

Victoria Steven, the charity's spokeswoman for Scotland, said: "This crucial investment recognises the fantastic research taking place in Glasgow".

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE